Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erbitux in advanced non-small cell lung cancer
NCT00315185Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Dec 2004
- Primary completion
- Jun 2007
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in non-small cell lung cancer (NSCLC), sponsored by Fox Chase Cancer Center. Started Dec 2004; status: completed.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00315185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00315185.